


RSC Advances



This article can be cited before page numbers have been issued, to do this please use: P. Funk, K. Motyka, P. Dzubak, P. Znojek, S. Gurska, J. Kusz, C. McMaster, M. Hajduch and M. Soural, *RSC Adv.*, 2015, DOI: 10.1039/C5RA08733C.



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



Journal Name

ARTICLE

Preparation of 2-Phenyl-3-hydroxyquinoline-4(1H)-one-5-carboxamides as Potential Anticancer and Fluorescence Agents

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

Petr Funk^a, Kamil Motyka^a, Petr Džubák^b, Paweł Znojek^b, Sona Gurska^b, Joachim Kusz^c, Claire McMaster^a, Marián Hajdúch^b, and Miroslav Soural^a

Synthesis of 3-hydroxyquinoline-4(1H)-one derivatives bearing substituted phenyl in position 2 and variously substituted carboxamide group in position 5 is described, with use of 3-nitrophthalic anhydride, α -haloketones and primary amines as the starting materials. The synthetic approach was inspired by the preparation of analogous derivatives reported previously. However, a different strategy had to be developed with the corresponding bis(phenacyl)-3-aminophthalates as the key intermediates. Synthesized hydroxyquinolinones, as well as their intermediates, were tested for their cytotoxic activity towards various cancer and non-malignant cell lines. The fluorescent properties of these compounds have also been evaluated. In both fields, interesting data were obtained and compared to isomeric compounds that have been studied in the past.

Introduction

In the last decade, compounds bearing 3-hydroxyquinolin-4(1H)-one scaffold (3HQs) have been studied intensively due to their outstanding biological and spectral properties. In the field of medicinal chemistry, 3HQs exhibited significant cytotoxicity against selected cancer cell lines, indicating their possible application as novel anticancer agents.^{1–5} Consequently, the most promising compounds have been submitted for liposomal solubilization⁶ and micellar dispersion⁷ studies to increase their bioavailability and stability. Aside from cytotoxicity, hydroxyquinolinones also exhibited strong fluorescence with a dual emission spectra which pointed to their potential application in the area of molecular probes and fluorescence labeling.^{8–11} With use of the highly efficient method of preparation, discovered in the end of nineties,^{12–16} a number of variously substituted 3HQs have been synthesized and studied. Recently, a deeper attention has been paid to compounds bearing the carboxamide group located on a benzene ring of the quinolinone scaffold. For such compounds, a high-throughput solid-phase synthesis concept has been developed^{17–19} and targeted chemical libraries of 3HQs with the carboxamide group located in position 6, 7 and 8 were

prepared. Both structure-cytotoxicity^{20,21} and structure-fluorescence²² relationships have been evaluated and derivatives with the most promising biological and fluorescence properties were identified (Figure 1).




Figure 1: Solid-phase strategy for the preparation of 6-8 carboxamides described previously^{17,20} and properties of selected compounds

Despite detailed research into this field, a aforementioned studies were incomplete due to the impossibility to apply the original solid-phase approach to the preparation of isomers with the carboxamide group located in position 5. To reach this goal, we switched to traditional solution-phase chemistry to find a synthetic strategy for the desired compounds. Herein we describe the method development, its application for the preparation of a set of target derivatives and comparisons of their cytotoxic/fluorescence properties with the corresponding 6-8-carboxamides.

Results and discussion

Synthesis

^a Department of Organic Chemistry, Institute of Molecular and Translational Medicine, Faculty of Science, Palacký University, 771 46 Olomouc, Czech Republic

^b Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Hněvotínská 5, CZ-775 15 Olomouc, Czech Republic


^c Institute of Physics, University of Silesia, 4 Uniwersytecka Street, PL-40-007 Katowice, Poland

† Electronic Supplementary Information (ESI) available: See DOI: 10.1039/x0xx00000x

ARTICLE

Journal Name


The initial strategy (Scheme 1) was based on the method of preparation of the corresponding 6-8 carboxamides reported previously.¹⁷ In such cases the key building block was 3-amino-2-(methoxycarbonyl)benzoic acid **3**. We managed to synthesize the compound from 3-nitrophthalic anhydride **1** via intermediate **2** according to described procedures.^{23,24} However, the crude purity of compound **3** after the catalytic reduction step was low. Conversion of carboxylic acid **3** to the corresponding amide was tested with propylamine. Unfortunately, the attempt to synthesize compound **4** with use of the DIC/HOBt method afforded the product, only as a part of a complex mixture. We subsequently reversed the reaction sequence and propylamine was acylated directly with compound **2** via the corresponding acylchloride. In this case, the expected product was not obtained and the reaction afforded pure 4-nitro-2-propylisindoline-1,3-dione **5**. Although we managed to hydrolyze the intermediate **5** to yield 2-nitro-6-(propylcarbamoyl)benzoic acid **6**, its catalytic hydrogenation led only to a mixture of compounds and the desired product **7** was not isolated. Additionally, alkylation of acid **6** with bromoacetophenone did not lead to the corresponding phenylester (which could be also applied for the preparation of target 3HQs) but intermediate **5** was detected instead.



Scheme 1: Attempt to synthesize methyl 2-amino-6-(propylcarbamoyl)benzoate **7** according to previously reported procedure


The alternative strategy was based on the preparation of bis(phenacyl)-3-aminophthalates **13** as the precursors for the formation of the 3HQ scaffold. Due to limited purity after catalytic reduction of compound **2**, dimethylester **8** was synthesized first, via the formation of the corresponding acylchloride. Subsequent reduction afforded compound **9** in an excellent purity which was smoothly hydrolyzed to obtain pure 3-aminophthalic acid **10**. Compound **10** was alkylated with bromoacetophenone to give bis(phenacyl)-3-aminophthalate **13a**. It is worth mentioning that an alternative strategy based on the hydrolysis of compound **8** followed by alkylation of intermediate **11** failed in the stage of catalytic hydrogenation of compound **12**, which afforded only a complex mixture of compounds (Scheme 2). Cyclization of intermediate **13a** to 3HQ derivative **14a** was performed with use of TFA as described earlier for similar derivatives.¹² The final step of the sequence was aminolysis of compound **14a** with propylamine to obtain final 3HQ **15a**. Two methods have been developed:

Reflux with propylamine in chloroform (10% solution) was successfully used on a small scale (milligram quantities). On a larger scale (quantities above 100 mg), the method was not successful due to an incomplete conversion and chloroform had to be replaced by DMF.



Scheme 2: Strategy for the preparation of bis(phenacyl)-3-aminophthalates **13a**

For fluorescence and biological assay purposes we also managed to develop re-esterification of compound **14a** to prepare methyl derivative **16a** (Scheme 3).




Scheme 3: Conversion of intermediate **13a** to hydroxyquinolinone derivative **15a**

With use of developed procedures, a set of model compounds (Table 1) were prepared from various bromoacetophenones and amines (Figure 2). To allow for the comparative study of the structure-cytotoxicity and structure-fluorescence relationship, we selected the same building blocks and their combinations as used previously for the preparation of 6-8 carboxamides.^{20,21} The developed procedure was generally applicable, only the cyclization of intermediate **13h** had to be performed in anhydrous phosphoric acid instead of TFA which did not work.

Fluorescence properties

2-Aryl-3-hydroxyquinolin-4(1*H*)-ones typically exhibit dual fluorescence spectrum with two sufficiently separated emission bands, which allows for their possible application as fluorescent labels.^{10,11} Type/location of different substituents on the 3HQ scaffold can significantly affect the emission spectra. In the case of different isomeric 3HQ-carboxamides, we have already reported that positioning of the carboxamide group strongly influences the resulting fluorescence properties: 6-Carboxamides exhibited two well separated maxima whereas 8-carboxamides provided only one emission maximum at lower wavelength and extremely low quantum yields.²²



Entry	Cmpd.	R ¹	R ²	Yield ^a (%)
1	13a	H	-	70
2	13b	3,5-diCl-4-NH ₂	-	68
3	13c	4-CH ₃	-	84
4	13d	4-OCH ₃	-	65
5	13e	4-F	-	82
6	13f	3-Br	-	77
7	13g	3-NO ₂ -4-Cl	-	68
8	13h	3-NO ₂ -4- <i>N</i> -PIP	-	87
9	14a	H	-	88
10	14b	3,5-diCl-4-NH ₂	-	87
11	14c	4-CH ₃	-	93
12	14d	4-OCH ₃	-	84
13	14e	4-F	-	90
14	14f	3-Br	-	95
15	14g	3-NO ₂ -4-Cl	-	81
16	14h	3-NO ₂ -4- <i>N</i> -PIP	-	79
17	15a	H	Propyl	35
18	15b	3,5-diCl-4-NH ₂	Propyl	45
19	15c	4-CH ₃	Propyl	64
20	15d	4-OCH ₃	Propyl	40
21	15e	4-F	Propyl	31
22	15f	3-Br	Propyl	81
23	15g	3,5-diCl-4-NH ₂	Hydroxyethyl	35
24	15h	3,5-diCl-4-NH ₂	-	24
25	15i	3,5-diCl-4-NH ₂	Benzyl	34
26	15j	3,5-diCl-4-NH ₂	H	30
27	16a	H	-	34
28	16b	3,5-diCl-4-NH ₂	-	32

^aCalculated after the cyclization step

Table 1: List of synthesized 3HQs and bis(phenacyl)-3-aminophthalates

The difference could be explained by the strong intramolecular hydrogen bonding in the structure of 8-carboxamides which does not exist in the case of the 6- and 7-carboxamide analogues (Figure 3).




Figure 2: List of used haloketones and amines





Figure 3: Different sterical features of isomeric 3HQ-carboxamides

A different situation was expected in the structure of 5-carboxamides; the steric repulsion between two carbonyl groups enforces the conformation in which the carboxamide is not in the same plain with the aromatic moiety and conjugation is lost. This fact has been proved by X-ray analysis of compound **15a** (Picture 1). However, the consequence of this feature to the resulting fluorescence and biological properties was unclear.



Picture 1: X-ray analysis of compound **15a**. Hydrogen atoms have been omitted for the sake of clarity. Displacement ellipsoids are drawn at the 50% probability level.

From the initial results of the fluorescence study in dimethyl sulfoxide (DMSO), it was evident that the existence of the dual fluorescence spectrum was not significantly affected by the location of the carboxamide group at position 5. Although the intensity of the lower wavelength maximum was reduced (Figure 4, solid line), it was still noticeable and resembled the emission spectra of 7-carboxamides.²² On the other hand, the presence of the methyl ester instead of carboxamide (3HQs **16a**, **16b**) led to complete loss of the emission maximum at lower wavelength and the dual fluorescence spectrum was not detected. 3HQs **14** with the phenacyl ester moiety did not give consistent results: For the

majority of them the dual fluorescence spectrum was lost, only two 3HQs **14a** and **14f** provided the second (higher wavelength) emission maximum. In contrast, 3HQ **14g** afforded only the lower wavelength emission maximum (Table 2) and compound **14h** did not exhibit any fluorescence at all. To highlight the key effect of the 3HQ scaffold, we have also studied bis(phenacyl)esters **13**. Although their fluorescence has been observed, the dual fluorescence spectra were not obtained and their emission maximum was significantly lower compared to 3HQs (520–560 nm for 3HQs **14–16**, 454–480 for compounds **13**).




Figure 4: Excitation and emission spectra for **13c** (dash line), **15d** (solid line) and **16a** (dotted line).

Quantum yields within the group of 5-carboxamides **15** were mostly similar, although slightly lower compared to analogical 6/7-carboxamides.²² Nonetheless, there was no clear relationship between their values and the structural features of these molecules. A quite different situation was observed for phenacyl-3HQs **14** which provided a wide range of values from 0.72% to 28.9%. It could be concluded that the presence of 2-phenyl with strongly electron withdrawing groups (such as nitro, fluoro) significantly diminished the quantum yields (compounds **14g** and **14h**), whereas compounds with electron-donating groups (such as methoxy, amino, methyl) provided higher values. Similar dependence have been observed for bis(phenacyl)esters **13**.

The study was further expanded to evaluate the relationship between fluorescence properties and pH. For this purpose, representative compounds **13c**, **14a**, **15d** and **16a** with the highest quantum yields and/or dual-band spectra were selected. The pH measurements were performed in a solution consisting of 9:1 v/v 0.1 M phosphate buffer/dimethyl sulfoxide with the concentration of investigated compound being 10 $\mu\text{g.mL}^{-1}$. Surprisingly, in aqueous solution the emission spectra totally lost their dual character. The loss of the dual shape of emission spectra did not enable us to apply the ratio of the maximum intensities as a signal. The intensity ratio does not usually depend on the label concentration which is an important advantage in complex biological

systems, such as cells or tissues, where the local concentration of the dye cannot be easily controlled and generally the label is not distributed homogeneously. In each studied case, the emission spectra retained the same shape at different pHs, whereas the fluorescence intensity changed (Figure 5). The maximum fluorescence intensity was reached at pH 3.60, 6.41, 5.23 and 5.75 for **13c**, **14a**, **15d** and **16a**, respectively. The pH dependences of fluorescence intensity had a similar shape for all investigated compounds: At acidic pH values the fluorescence intensity increased with increasing pH, reached the maximum and then gradually decreased (Figure 5, below). In spite of the fact that the ratiometric measurement was not possible, the pH dependence of fluorescence intensity for **13c** was linear ($y = -8.7349x + 132.15$, $R^2 = 0.9936$) in the pH range 4.62–9.22 which could be beneficial, especially for biological measurement.

Entry	Cmpd	λ_{exc} (nm) ^a	$\lambda_{\text{em},1}$ (nm) ^b	$\lambda_{\text{em},2}$ (nm) ^c	I_2/I_1 ^d	Φ (%) ^e
1	13a	394	474	-	-	43.43
2	13b	373	467	-	-	16.65
3	13c	390	464	-	-	48.67
4	13d	371	454	-	-	20.15
5	13e	373	462	-	-	3.66
6	13f	394	474	-	-	19.87
7	13g	394	472	-	-	5.43
8	13h	395	480	-	-	0.17
9	14a	402	474	555	0.1158	11.20
10	14b	413	-	560	-	19.57
11	14c	405	-	555	-	10.44
12	14d	403	-	560	-	28.91
13	14e	404	-	556	-	10.84
14	14f	407	478	555	0.0990	7.26
15	14g	419	481	-	-	0.72
16	14h	-	-	-	-	-
17	15a	403	449	527	0.1024	36.14
18	15b	409	467	531	0.0627	37.63
19	15c	404	464	526	0.1025	14.76
20	15d	400	454	525	0.1146	38.61
21	15e	404	455	528	0.1123	42.54
22	15f	403	457	520	0.0698	30.80
23	15g	415	456	532	0.0602	42.74
24	15h	411	468	532	0.0893	24.11
25	15i	410	461	531	0.0683	37.10
26	15j	412	471	530	0.0855	25.51
27	16a	402	-	547	-	39.78
28	16b	416	-	554	-	29.96

^a λ_{exc} , excitation wavelength.

^b $\lambda_{\text{em},1}$, the fluorescence emission maximum at lower wavelengths.

^c $\lambda_{\text{em},2}$, the fluorescence emission maximum at higher wavelengths.

^d I_2/I_1 , the ratio of fluorescence maxima intensities.

^e Φ , fluorescence quantum yield (determined with quinine sulphate in 0.5 M sulphuric acid ($\Phi = 0.577^{25}$), taken as a reference fluorescence standard).

Table 2: Fluorescence properties of synthesized compounds (measured in dimethyl sulfoxide, conc. 0.1 mg.mL^{-1}).

Cytotoxic activity

To allow for the structure-activity relationship studies, the synthesized compounds were screened against the same cancer cell lines as their analogues, that have previously been studied: CCRF-CEM (T-lymphoblastic leukaemia), CEM-DNR (T-lymphoblastic leukaemia, daunorubicin resistant), K562 (acute

myeloid leukaemia) and K562-TAX (acute myeloid leukaemia, paclitaxel resistant), A549 (human lung adenocarcinoma), HCT116 (human colorectal cancer), HCT116p53^{-/-} (human colorectal cancer, p53 deficient), U2OS (human osteosarcoma). The therapeutic index (TI) was evaluated using one representative of non-malignant cell lines – BJ (human fibroblasts). The obtained results are summarized as the IC₅₀ values in Table 3.




Figure 5: Illustrative emission spectra of **13c** (red, solid line pH 5.75, dashed line pH 7.69 and dotted line pH 12.49), **14a** (green, solid line pH 6.43, dashed line pH 11.53 and dotted line pH 12.49), **15d** (black, solid line pH 3.60, dashed line pH 6.49 and dotted line pH 12.49) and **16a** (blue, solid line pH 5.75, dashed line pH 8.58 and dotted line pH 11.63) and fluorescence intensity at different pH.

As in the case of bisphenacyl-2-aminoterephthalates,² the corresponding bisphenacyl-3-aminophthalates **13** did not exhibit significant cytotoxic activity. However, an exception has been observed for compound **13g** which showed a medium cytotoxicity against K562-TAX, U2OS and CEM cells. Within the group of HQ-5-carboxamides **15**, the similar SAR pattern as for analogical 6-8 carboxamides was observed: The highest activity was detected for 2-(3,5-dichloro-4-aminophenyl)-3HQs with unpolar *N*-alkyl substituents (**15b**:*N*-propyl and **15i**:*N*-benzyl), whereas the unsubstituted carboxamide **15j** and compounds with polar (**15g**:*N*-hydroxyethyl) or basic (**15h**:*N*-piperidinyl-ethyl) ligands were not cytotoxic. Structural change of propylamides (**15a,b**) to the

corresponding methylesters (**16a,b**) provided approximately the same results. On the other hand, cytotoxicity of 3HQs-5-phenacylestes **14** was in general significantly higher, with compound **14b** being the most active derivative from the whole set. IC₅₀ of aminophthalate **14b** for A-549, K56A, CEM, K562-TAX and CEM-DNR was comparable to isomeric aminoterephthalate.² In contrast, 4-methylphenyl phthalate derivative **14c** was inactive compared to isomeric aminoterephthalate that exhibited micromolar IC₅₀ for all tested lines.² The reversed dependence was observed for the unsubstituted phenacylester **14a** (Figure 6). The majority of active compounds were less active against the CEM-DNR multidrug resistant cell line overexpressing the multidrug resistance protein 1 (MRP-1), than against highly chemosensitive parental CCRF-CEM cell line. However, the opposite pattern was identified in the case of P glycoprotein (Pgp-1) overexpressing multidrug resistant K562-TAX cell line which was more sensitive than parental K562 cell line. Interestingly, CEM-DNR cells also lack topoisomerase II α gene, which has been previously reported as a molecular target for quinolone derivatives. It is suggesting either the topoisomerase II α as a molecular target for 3HQs-5-phenacylestes **14** or involvement of MPR-1 but not Pgp-1 in drug efflux and resistance mechanisms.²⁶ The growth inhibitory activity of compounds against human colorectal cancer cell line HCT116 and its p53 deficient counterpart (HCT116p53^{-/-}) were similar, thus indicating independence of cell death mechanism on the p53 gene. The therapeutic index of the most active compound **14b** ranged from 15-30 for majority of cell lines, suggesting preferential activity against malignant cells.

Finally, two representative compounds were subjected to the fluorescent microscopy assay. We selected the most cytotoxic compound **14b** along with the most active carboxamide derivative **15i**. The results are depicted in Picture 2. The microscopy imaging is showing that the fluorescent compounds are penetrating cellular membranes of living cells. The highest intensity of the fluorescence and accumulation of the compound was observed in the cytoplasm, with discrete nuclear spots. Maximum cytoplasmic positivity was seen in perinuclear region, the staining pattern was overlapping in both emission wavelengths. Detailed subcellular localization is to be determined in future studies.

Conclusions

We have developed a synthetic procedure for 3HQs-5-carboxamides **15** to enable the study of their properties compared to analogical 6-8 isomers. In the field of fluorescence properties, the synthesized 5-carboxamides exhibited similar results to their 7-isomers that have previously been studied. In this regard, some derivatives showed a potential to serve as pH indicators and/or molecular probes. Based on the fluorescence microscopy imaging of U2OS cells treated with two representative compounds **14b** and **15i** it was demonstrated, that compounds enter live cells and show preferential cytoplasmic staining. The cytotoxicity of 3HQs-5-

carboxamides towards various cancer cell lines corresponded to 8-carboxamides. The overall results show that the location of the carboxamide group in position 5 rather decreases the cytotoxicity activity compared to 6,7-carboxamides, however, the evaluation of SAR data revealed the same pattern. Higher cytotoxicity was detected for 3HQs-5-phenacylesters **14**. The most active compound **14b** exhibited the similar activity as the corresponding 7-phenacylester described previously. On the other hand, the SAR pattern observed within the group of available 5- and 7-phenacylesters showed an interesting differences based on the location of the phenacylester moiety. To explore the field in further details, 3HQs-6-phenacylesters and 3HQs-8-phenacylesters will be synthesized and systematically studied for biological activities and fluorescence probing properties.

Cmpd.	CCRF-CEM	CEM-DNR	K562	K562-TAX	A549	HCT116	HCT116 p53 -/-	U2OS	BJ
13a	>50	>50	>50	>50	>50	43	>50	>50	>50
13b	>50	48	>50	>50	>50	>50	>50	>50	>50
13c	>50	46	>50	>50	>50	>50	>50	>50	>50
13d	>50	>50	>50	>50	>50	>50	>50	>50	>50
13e	>50	>50	>50	>50	>50	>50	>50	>50	>50
13g	12	37	17	8.3	>50	30	19	12	>50
13h	>50	>50	>50	>50	>50	>50	>50	>50	>50
14a	2.7	8.1	8.6	6.0	9.5	12	4.0	10	10
14b	0.8	4.5	1.5	0.8	2.3	1.6	1.4	2.4	25
14c	40	>50	>50	42	>50	>50	>50	>50	>50
14d	2.7	8.8	7.6	4.2	13	6.5	4.0	10	>50
14e	2.2	6.7	13	4.0	23	3.5	3.3	5.4	36
14f	2.3	2.3	1.3	4.6	6.4	3.0	2.7	10	34
14g	20	24	38	6.2	12	8.7	11	7.7	26
14h	32	>50	>50	13	>50	12	32	>50	>50
15a	10	26	>50	31	>50	20	19	23	>50
15b	7.7	23	15	8.8	34	7.5	7.2	12	34
15c	22	39	32	26	>50	27	20	>50	>50
15d	28	44	48	35	>50	30	27	>50	>50
15e	16	36	>50	32	>50	21	17	46	45
15f	4.3	13	25	10	24	7.9	8.0	14	>50
15g	31	>50	49	48	>50	42	39	47	>50
15h	34	>50	36	>50	48	25	27	46	40
15i	3.3	10	2.5	4.6	6.9	24	4.0	10	8.6
15j	34	48	45	30	49	20	18	27	45
16a	15	49	>50	>50	>50	>50	46	17	>50
16b	4.7	6.7	5.8	4.6	27	5.5	4.6	9.3	9.8

Table 3: Results of cytotoxicity for all synthesized compounds (relative IC₅₀, μ M). Average values from 3-4 independent experiments with SD ranging from 10-25% of the average values





Figure 6: Example of 3HQs-phenacylesters cytotoxicity dependence on the location of the ester group (for K562 cell line)



Picture 2: U2OS osteosarcoma cancer cells treated with **14b** (first row) and **15i** (second row). Full size images are available in SI.

Acknowledgements

The authors are grateful to projects CZ.1.07/2.3.00/30.0060, CZ.1.07/2.3.00/30.0041 from the European Social Fund, from Palacky University (Internal Grant No. IGA_PrF_2015_007, IGA_LF_2015_031), National Sustainability Programme (LO1304) and Czech Technology Agency (TE02000058).

Notes and references

- P. Hradil, P. Krejčí, J. Hlaváč, I. Wiedermannová, A. Lyčka, V. Bertolasi, *J. Heterocyclic Chem.*, 2004, **41**, 375-379.
- M. Soural, J. Hlaváč, P. Hradil, I. Fryšová, M. Hajdúch, V. Bertolasi, M. Maloň, *Eur. J. Med. Chem.*, 2006, **41**, 467-474.
- P. Hradil, J. Hlaváč, M. Soural, M. Hajdúch, M. Kolář, R. Večeřová, *Mini-Rev. Med. Chem.*, 2009, **9**, 696-702.
- P. Krejčí, P. Hradil, J. Hlaváč, M. Hajdúch WO2008028427 A1
- Z. Sui, V.N. Nguyen, J. Altom, J. Fernandez, J.J. Hilliard, J.I. Bernstein, J.F. Barrett, K.A. Ohemeng, *Eur. J. Med. Chem.*, 1999, **34**, 381-387.
- M. Di Cagno, P.C. Stein, J. Stýskala, J. Hlaváč, N. Skalko-Basnet, A. Brauer-Brandl, *Eur. J. Pharm. Biopharm.*, 2012, **80**, 657-662.
- M. Di Cagno, J. Stýskala, J. Hlaváč, M. Brandl, A. Brauer-Brandl, N. Skalko-Basnet, *J. Liposome Res.*, 2011, **21**, 272-278.
- K. Motyka, B. Vankova, J. Hlaváč, M. Soural, *J. Fluoresc.*, 2011, **21**, 2207-2212.
- K. Motyka, J. Hlaváč, M. Soural, P. Hradil, P. Krejčí, L. Kvapil, M. Weiss, *Tetrahedron Lett.*, 2011, **52**, 715-717.
- D.A. Yushchenko, V.V. Shvadchak, A.S. Klymchenko, G. Duportail, Y. Mely, V.G. Pivovarenko, *New J. Chem.*, 2006, **30**, 774-781.
- D.A. Yushchenko, M.D. Bilokin, O.V. Pyvovarenko, G. Duportail, Y. Mely, V.G. Pivovarenko, *Tetrahedron Lett.*, 2006, **47**, 905-908.
- M. Soural, P. Hradil, S. Křupková, J. Hlaváč, *Mini-Rev. Org. Chem.*, 2012, **9**, 426-432.

Journal Name

ARTICLE

- 13 P. Hradil, J. Jirman, *Collect. Czech. Chem. Commun.*, 1995, **60**, 1357-1366.
- 14 P. Hradil, J. Vanecek, J. Hlavac, J. Sevcik, *Collect. Czech. Chem. Commun.*, 1999, **64**, 257-264.
- 15 P. Hradil, J. Hlaváč, P. Krejčí, K. Lemr, *Acta Univers. Palack. Olom.*, 1999, **38**, 17-23.
- 16 P. Hradil, J. Hlaváč, K. Lemr, *J. Heterocyclic Chem.*, 1999, **36**, 141-144.
- 17 M. Sural, V. Krchnak, *J. Comb. Chem.*, 2007, **9**, 793-796.
- 18 B. Vankova, J. Hlavac, M. Sural, *J. Comb. Chem.*, 2010, **12**, 890-894.
- 19 S. Krupkova, M. Sural, J. Hlavac, P. Hradil, *J. Comb. Chem.*, 2009, **11**, 951-955.
- 20 M. Sural, J. Hlavac, P. Funk, P. Dzubak, M. Hajduch, *ACS Combi. Sci.*, 2011, **13**, 39-44.
- 21 J. Kadric, K. Motyka, P. Džubák, M. Hajdúch, M. Sural, M. *Tetrahedron Lett.*, 2014, **55**, 3592-3595.
- 22 K. Motyka, J. Hlaváč, M. Sural, P. Funk, P., *Tetrahedron Lett.*, 2010, **51**, 5060-5063.
- 23 L. Marinus, L. Eur. Pat. Appl., 133310, 20 Feb 1985
- 24 C. Banzatti, N. Carfagna, R. Commisso, F. Heidempergher, L. Pegrassi, P. Melloni, *J. Med. Chem.*, 1988, **31**, 1466-1471.
- 25 W.H. Melhuish, *J. Phys. Chem.* 1961, **65**, 229-235.
- 26 V. Noskova, P. Dzubak, G. Kuzmina, A. Ludkova, D. Stehlik, R. Trojanec, A. Janostakova, G. Korinkova, V. Mihal, M. Hajduch, *Neoplasma* 2002, **49**, 418-425.